GLYC

GlycoMimetics (GLYC)

GlycoMimetics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:GLYC

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/11/12	22:00	PR Newswire (US)	Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024	NASDAQ:GLYC	GlycoMimetics Inc
2024/11/08	06:47	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:GLYC	GlycoMimetics Inc
2024/11/08	06:42	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GLYC	GlycoMimetics Inc
2024/11/07	07:41	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:GLYC	GlycoMimetics Inc
2024/11/06	21:00	Business Wire	GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting	NASDAQ:GLYC	GlycoMimetics Inc
2024/11/05	06:26	Edgar (US Regulatory)	Form SC 13D - General Statement of Acquisition of Beneficial Ownership	NASDAQ:GLYC	GlycoMimetics Inc
2024/11/05	04:01	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:GLYC	GlycoMimetics Inc
2024/10/29	23:00	AllPennyStocks.com	Shares of Biotech Company Up Over 100% Premarket Following Merger & Funding Announcement	NASDAQ:GLYC	GlycoMimetics Inc
2024/10/29	23:00	AllPennyStocks.com	Biotech Up Over +100% Premarket Following Merger And Funding Announcement	NASDAQ:GLYC	GlycoMimetics Inc
2024/10/29	21:09	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:GLYC	GlycoMimetics Inc
2024/10/29	21:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GLYC	GlycoMimetics Inc
2024/10/29	20:00	Business Wire	GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma	NASDAQ:GLYC	GlycoMimetics Inc
2024/10/29	19:30	Business Wire	GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint	NASDAQ:GLYC	GlycoMimetics Inc
2024/08/16	06:01	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:GLYC	GlycoMimetics Inc
2024/08/15	05:13	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:GLYC	GlycoMimetics Inc
2024/08/09	05:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:GLYC	GlycoMimetics Inc
2024/07/31	04:55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GLYC	GlycoMimetics Inc
2024/07/30	08:24	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:GLYC	GlycoMimetics Inc
2024/07/25	22:00	Business Wire	GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan	NASDAQ:GLYC	GlycoMimetics Inc
2024/06/14	05:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GLYC	GlycoMimetics Inc
2024/06/04	22:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GLYC	GlycoMimetics Inc
2024/06/04	20:00	Business Wire	GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)	NASDAQ:GLYC	GlycoMimetics Inc
2024/05/30	05:01	Business Wire	GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024	NASDAQ:GLYC	GlycoMimetics Inc
2024/05/10	05:31	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:GLYC	GlycoMimetics Inc
2024/05/07	05:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GLYC	GlycoMimetics Inc
2024/05/06	19:00	Business Wire	GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)	NASDAQ:GLYC	GlycoMimetics Inc
2024/04/25	20:00	Business Wire	GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024	NASDAQ:GLYC	GlycoMimetics Inc
2024/03/27	20:00	Business Wire	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023	NASDAQ:GLYC	GlycoMimetics Inc
2024/03/13	20:00	Business Wire	GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024	NASDAQ:GLYC	GlycoMimetics Inc
2024/03/01	23:16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GLYC	GlycoMimetics Inc